Renal dosing and indication
Enoxaparin in severe renal impairment: prophylaxis is not treatment
A renal adjustment is not a single dose that fits every use of enoxaparin. The Lovenox label separates prevention from treatment and gives different severe-renal-impairment regimens.
Sources checked October 13, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Start with the purpose of the prescription
The label has separate regimens for prophylaxis after surgery or during acute medical illness, treatment of DVT, and acute coronary syndromes. A medicine name and renal value are not enough to identify the intended regimen.
A common case error is to see severe renal impairment and choose 30 mg daily for everyone. That is a prophylaxis amount for the uses listed in the table, not a substitute for its weight-based DVT treatment entry.
Use the current severe-renal table
The manufacturer label revised May 2025 gives severe renal impairment as CrCl below 30 mL/min. Its listed abdominal-surgery, hip-or-knee-replacement and acute-medical-illness prophylaxis regimens are 30 mg subcutaneously once daily.
For inpatient or outpatient treatment of acute DVT, with or without PE, when administered with warfarin, the table gives 1 mg/kg subcutaneously once daily. Preserve the frequency as well as the amount. A correct milligram calculation at the wrong interval is still wrong.
Do the arithmetic only after selecting the row
For a hypothetical 70 kg patient in the stated DVT-treatment setting with CrCl 24 mL/min, the weight-based amount is 70 mg once daily under that table. A proposed 30 mg once daily matches a different purpose; 70 mg every twelve hours misses the severe-renal frequency.
The example does not decide whether the person should receive enoxaparin and warfarin rather than another anticoagulation plan. It isolates a labeled regimen check. Actual dosing also needs bleeding risk, platelets, timing of procedures and the supplied product.
Do not ignore monitoring and procedure risks
Enoxaparin can cause bleeding and carries a boxed warning about spinal or epidural hematomas with neuraxial procedures. A dose adjustment does not eliminate those concerns. The label also requires attention to heparin-induced thrombocytopenia history and platelet monitoring.
The cited label does not recommend adjustment for CrCl 30 to 50 mL/min but says to observe for bleeding. Do not translate no labeled adjustment into no safety assessment. Renal function may change during acute illness, so an old estimate is not a permanent dosing guarantee.
A worked case
A fictional 70 kg adult with CrCl 24 mL/min has acute DVT and is receiving warfarin. A draft changes enoxaparin to 30 mg daily because that is the renal dose. Use the current severe-renal table to assess it.
- Identify treatment of DVT, not prophylaxis.
- The table uses 1 mg/kg once daily for this stated treatment setting.
- 70 kg x 1 mg/kg = 70 mg once daily, not the prophylaxis amount.
Answer: The draft selected the wrong indication row. The stated treatment entry gives 70 mg subcutaneously once daily, subject to the full clinical review.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Is 30 mg daily the severe-renal dose for every indication?
No. It is used for the listed prophylaxis settings, not the weight-based DVT treatment row.
2. What threshold defines severe renal impairment in this table?
CrCl below 30 mL/min.
3. Does a correct amount excuse an incorrect frequency?
No. Both must match the intended regimen.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.